TrialNature medicine2023

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.

Roch Houot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.